Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer

British Journal of Cancer

Volumn 109, Issue 1, 2013, Pages 50-59

  Blick, C ^a   Ramachandran, A ^a,b   Wigfield, S ^a   McCormick, R ^a   Jubb, A ^a   Buffa, F M ^a   Turley, H ^a   Knowles, M A ^c   Cranston, D ^d   Catto, J ^e   Harris, A L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 100; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; NON MUSCLE INVASIVE BLADDER CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; WESTERN BLOTTING;

CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICRORNAS; NEOPLASM INVASIVENESS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 84880255880     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.240     Document Type: Article

References (48)

1. Brahimi-Horn MC, Pouyssegur J (2009) HIF at a glance. J Cell Sci 122(Pt 8): 1055-1057.
2. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J (2011) microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71(17): 5635-5645.
3. Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102(2): 428-435.
4. Cairo S, Wang Y, de Reynies A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA (2010) Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci USA 107(47): 20471-20476.
5. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T (2005) MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21(13): 2933-2942.
6. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28(4): 401-408.
7. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69(21): 8472-8481.
8. Chai CY, Chen WT, Hung WC, Kang WY, Huang YC, Su YC, Yang CH (2008) Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 61(5): 658-664.
9. Dai H, Holm R, Kristensen GB, Abeler VM, Borresen-Dale AL, Helland A (2001) Fibroblast growth factor receptor 3 (FGFR3): analyses of the S249C mutation and protein expression in primary cervical carcinomas. Anal Cell Pathol 23(2): 45-49.
10. Foldynova-Trantirkova S, Wilcox WR, Krejci P (2012) Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat 33(1): 29-41.
11. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S (2007) Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA 104(32): 13092-13097.
12. Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stattner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B (2011) Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 53(3): 854-864.
13. Goebell PJ, Knowles MA (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28(4): 409-428.
14. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25(5): 387-392.
15. Houghton P, Fang R, Techatanawat I, Steventon G, Hylands PJ, Lee CC (2007) The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods 42(4): 377-387.
16. Ioachim E, Michael M, Salmas M, Michael MM, Stavropoulos NE, Malamou- Mitsi V (2006) Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int 77(3): 255-263.
17. Koumenis C, Wouters BG (2006) "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 4(7): 423-436.
18. L'Hote CG, Knowles MA (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 304(2): 417-431.
19. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA (2011) Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 104(1): 75-82.
20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4): 402-408.
21. Luis NM, Lopez-Knowles E, Real FX (2007) Molecular biology of bladder cancer. Clin Transl Oncol 9(1): 5-12.
22. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE (2011) Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res 17(15): 5016-5025.
23. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal JI (2005) Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11(17): 6280-6290.
24. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Siefker-Radtke A, Dinney C, Czerniak B (2010) Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 28(4): 429-440.
25. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ (2009) Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284(25): 16767-16775.
26. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 24(2): 447-463.
27. Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, Summerhayes IC (2010) A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 28(1): 39-48.
28. Office for National Statistics, C. S. r. R. o. c. d. i., England. Series MB1 no. 37. National Statistics: London
29. Ord JJ, Agrawal S, Thamboo TP, Roberts I, Campo L, Turley H, Han C, Fawcett DW, Kulkarni RP, Cranston D, Harris AL (2007) An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol 178(2): 677-682.
30. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-Harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, Fuller GN, Chen K, Lang FL, Nykter M, Zhang W (2013) The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 123(2): 855-865.
31. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3(4): 347-361.
32. Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17(3): 118-126.
33. Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27(3): 289-293.
34. Pollard C, Smith SC, Theodorescu D (2010) Molecular genesis of non-muscleinvasive urothelial carcinoma (NMIUC). Expert Rev Mol Med 12: e10.
35. Sayan AE, D'Angelo B, Sayan BS, Tucci P, Cimini A, Ceru MP, Knight RA, Melino G (2010) p73 and p63 regulate the expression of fibroblast growth factor receptor 3. Biochem Biophys Res Commun 394(3): 824-828.
36. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455(7209): 58-63.
37. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Aldape K, Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A, Rabadan R, Iavarone A (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337(6099): 1231-1235.
38. Tickoo SK, Milowsky MI, Dhar N, Dudas ME, Gallagher DJ, Al-Ahmadie H, Gopalan A, Fine SW, Ishill N, Bajorin DF, Reuter VE (2011) Hypoxiainducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int 107(5): 844-849.
39. Tomlinson DC, Baldo O, Harnden P, Knowles MA (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213(1): 91-98.
40. Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak PA, Jorde LB, Whitby FG, Longo N, Viskochil DH, Carey JC, Bamshad MJ (2006) A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am J Hum Genet 79(5): 935-941.
41. Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D, Harris AL (2002) The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 86(8): 1276-1282.
42. Wang X, Schneider A (2010) HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 31(7): 1202-1210.
43. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, Maxwell PH (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92(7): 2260-2268.
44. Winning S, Splettstoesser F, Fandrey J, Frede S (2010) Acute hypoxia induces HIF-independent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: the role of hypoxic inhibition of prolyl hydroxylase activity for the induction of NF-kappa B. J Immunol 185(3): 1786-1793.
45. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P, West CM, Harris AL (2007) Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67(7): 3441-3449.
46. Wood SM, Wiesener MS, Yeates KM, Okada N, Pugh CW, Maxwell PH, Ratcliffe PJ (1998) Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxiainducible gene expression. J Biol Chem 273(14): 8360-8368.
47. Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5(9): 713-725.
48. Zingone A, Cultraro CM, Shin DM, Bean CM, Morse 3rd HC, Janz S, Kuehl WM (2010) Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia 24(6): 1171-1178.